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Summary: Using commercially available radioimmune test kits, serial determinations of serum j32-microglobulin and
CEA were performed in 337 patients, who had been treated for breast cancer by modified radical mastectomy and
radiotherapy. The pre-therapeutic data indicated a higher incidence of pathological j32-microglobulin and CEA levels
in patients with distant metastases than in patients with localized disease. However, this finding did not allow the con-
clusion of a direct complementarity of j32-microglobulin and CEA as tumour markers, since the group of patients
with distant metastasis contained a high percentage of elderly patients who generally can be expected to have elevated
02-microglobulin serum concentrations. Therefore, the correlation of the clinical course of malignant disease and the
incidence of relapses with the changes of serum |32-microglobulin and CEA concentrations was examined during the
posMreatment surveillance: 7/9 cases (78%) with local recurrence and 46/73 cases (63%) with distant spread of
disease were not indicated in the |32-microglobulin follow-up by pathologic serum concentrations, whereas in the
CEA follow-up only 1/9 and 2/73 false negative indications were registered. The poor correlation suggests that serum
02-microglobulin is not directly tumour associated in breast cancer and does not fulfill the criteria of a tumour marker.
Vergleich von Serum ß2?Mikroglobulin und CEA in der klinischen Überwachung von Patienten mit Brustkrebs
Zusammenfassung: Routine-Bestimmungen von 02-Mikroglobulin und CEA im Serum wurden bei 337 Patienten mit
Brustkrebs unter Benützung kommerziell verfügbarer radioimmunologischer Tests durchgeführt. Alle Patienten wur-
den nach modifizierter radikaler Mastektomie und anschließender Radiotherapie weiter überwacht. Prätherapeutisch
wurden im Serum Konzentrationen von j32-Mikroglobulin und CEA im pathologischen Bereich wesentlich häufiger
bei Patienten mit Fernmetastasen beobachtet als bei Patienten mit lokalisiertem Tumorwachstum. Dieser Befund
ließ jedoch keinen direkten Rückschluß auf die Komplementarität von 02-Mikroglobulin und CEA als Tumormarker
zu, da die Patientengnippe mit Fernmetastasen einen hohen Prozentsatz von älteren Patienten enthielt, bei denen
allgemein eine erhöhte 02-Mikroglobulin Serurnkonzentration zu erwarten war. In der weiteren Überwachung wurde
daher die Korrelation des klinischen Verlaufs, insbesondere die Bildung von Rezidiven, mit zeitlichen Veränderungen
der /32-MikroglQbidin-und CEA-Konzentrationen im Serum überprüft: 7/9 Fällen (78%) mit Lokalrezidiven und
46/73 Fällen (63%) mit Fernmetastasen wurden in der./32-Mikroglobulin-Überwachung nicht durch pathologische
Konzentrationen im Serum angezeigt, während in der CEA-Ubewachung nur 1/9 und 2/73 falsch-negative Fälle
registriert wurden. Die geringe Korrelation weist daraufhin, daß.02-Mikrpglobülin im Serum in Brustkrebspatienten
nicht direkt mit Tumorwachstum assoziiert sein kann und die Kriterien eines Tumor-Markers nicht erfüllt.
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Introduction
Highly specific circulating tumour markers in sera of
patients with malignant clinical disorders are expected
to facilitate the management and postoperative surveil-
lance of cancer patients. In the management of breast
cancer patients a tumour marker of unique clinical value
has not yet been established. Carcinoembryonic antigen
(CEA) (1), an important parameter for disease progres-
sion as well as for the early detection of disease recur-
rence in gastrointestinal cancer (2-13), is of less clinical
significance in breast cancer, since pathologically elevated
serum levels of CEA were recorded in only about 50%
of cases (14,15). Therefore, the development of further
diagnostic parameters is of urgent necessity in order to
establish methods for a direct surveillance of tumour
growth and control of the efficacy of therapeutic efforts.
In recent years /32-microglobulin, the low molecular
weight component of the histocompatibility antigens
(16), has attracted considerable attention as a possible
tumour marker candidate. In a variety of malignant
disorders including carcinomas and lymphoid tumours
an elevated |32-microglobulin serum level was recorded
(17—26). However, the significance of these findings
still remains questionable in view of the paucity of data
relating the clinical course of malignant disease with the
changes in the serum /32-microglobulin level. Therefore,
in the present investigations special emphasis has been
put on the establishment of such a relationship, in order
to further characterize the possible role of /32-micro-
globulin as a tumour marker. The study was performed
with breast cancer patients who were treated by modified
radical mastectomy in various hospitals of our region
and were sent to the Medizinische Strahleninstitut in
Tübingen for postoperative radiotherapy 4—6 weeks
after surgery. For an additional direct comparison with
an established tumour marker, parallel determinations
of the serum concentration of j32-microglobulin and
CEA were carried out.
Patients and Methods
Patients
337 patients were registered in the study. Their ages varied from
30 to 85 years. All patients had been treated by modified radical
mastectomy. The tumour extension was staged by the surgeons
according to the clinical criteria (TNM) recommended by the
UICC. Information on involvement of axillary lymph nodes was
obtained from the pathologist's report.
All patients were thoroughly re-examined before radiotherapy
usually 4-6 weeks after mastectomy. The postsurgical treatment
of the patients was based on clinical conditions and diagnostic
details obtained from chest X-rays, bone and liver scans, computer
tomography and routine laboratory tests. Radiation treatment
varied with the clinical characteristics and the location of the
tumour. Details were given previously (27-28). During the
follow-up, patients had routine physical examinations connected
with catamnestic investigations and chest X-rays; they underwent
other diagnostic methods, when tumour progression or recurrence
was suspected.
Blood samples were generally obtained by peripheral venipunc-
ture a few days before radiotherapy, during hospitalization and
thereafter during routine clinical visits of the patients.
Methods
Serum /32-microglobulin was analyzed radioimmunologically
using the Phadebas-02-microtest (Pharmacia Diagnostics AB,
Uppsala, Sweden). The 02-microglobulin serum level of healthy
persons was reported to range between 0.8 and 2.4 mg/l (18, 29).
Thus, any 02-microglobulin serum concentration higher than
2.4 mg/l in our study was registered as "02-microglobulin
positive".
The concentration of CEA iri the sera was analyzed after per-
chloric acid extraction of the sera using the CEA-Roche-RIA
test kit (Roche Diagnostics). The CEA serum level of healthy
persons did not generally exceed 2.0 Mg/l (11). Thus, all CEA
serum concentrations above this level were recorded as "CEA
positive". This is slightly different from the critical level of CEA
determinations of plasma with a value of 2.5 jug/1 as recommended
by Roche Diagnostics.
Results
Correlation of preradiotherapeutic ß2-microglobulin
with CEA serum levels
Preliminary information on the possible role of /^-micro-
globulin as a tumour marker can be obtained from a
direct comparison of its serum concentration with that
of CEA. The study was performed with sera of breast
cancer patients in a blind trial and correlated with age
and tumour extension. Preradiotherapeutic serum samples
were only available in 163/337 cases. In table 1 the data
of/32-microglobulm and CEA assays of 163 preradio-
therapeutic serum samples are recorded and classified
into the following 4 criteria of CEA//32-microglobulin
serum levels:
1) samples with neither pathological |32-microglobulin
nor CEA levels;
2) samples with pathological (32-microglobulin but
normal CEA levels;
3) samples with normal |32-microglobulin and pathologi-
cal CEA levels;
4) samples with pathological levels of both ^ -micro-
globulin and CEA.
These data are listed for 5 age categories and 3 classes
of tumour extension.
The patients included in table 1 were selected for radio-
therapy, and are therefore not representative for newly
diagnosed breast cancer patients. The total percentage of
patients with pathological CEA concentrations was 67%
compared with that of patients with pathological j32-
microglobulin concentration (24%). About 8% of all
patients (13/163) in table 1 showed only pathological
02-microglobulm levels which might represent a gain in
characterization of malignant disease if the 2^micro-
globulin and CEA were complementary markers. For
patients with distant metastases already present at
mastectomy a significantly higher incidence of pathologi-
cal levels of both markers was recorded (tab. 1). More
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Tab. 1. Pre-radiotherapeutic serum â2-microglobulin und CEA levels in patients with breast cancer, who had undergone radical
mastectomy, correlated with age and tumour extension (TNM-classification) at primary mastectomy, (one patient = one value).
Specification Patients
Tumour extension:
T *0, No, Mo 64 39
T, N * 0, Mo 64 39
M = 1 35 22
Total 163 100
Samples with
Mg/l CEA/mg/l 0 2-microglobulin
20
18
3
41
3
7
3
13
34
33
16
83
7
6
13
26
Total samples
with elevated concentration
Age:
[a]
<40
40-49
50-59
60-69
>70
n
9
30
42
31
51
<2/<2.5 <2/>2.5 >2/<2.5 >2/>2.5
% n j Ð2 Ð3 Ð4
6
18
26
19
31
4
7
14
10
6
0
1
3
1
8
4
22
23
16
18
1
0
2
4
19
â 2-microglobulin
ç %
1
1
5
5
27
12
16
53
CEA
ç
5
22
25
20
37
%
55
73
60
65
73
10
13
16
39
16
20
46
24
41
39
29
109
64
61
83
67
ó»
JE
:§ 4
• ï °· So ß· ï ··" ï · · ï
2 10
CEA Uogjig/l]
100
Fig. 1. Semilogarithmic plot of the, pre-radiotherapeutic â 2-micro-
globulin and CEA serum concentrations of individual pa-
tients after modified radical mastectomy followed by
radiotherapy. Blood samples were taken 1 -4 days before
radiotherapy was started, the individual data are specified
by the tumour extension (TNM classification: ï = pa-
'tients with Tl-4, No, Mo; · = patients with Tlr-4, .
Nl-3,Mo; A = patients with Ml),
detailed information on the possibility of a direct associa-
tion of |32vmicroglobulin and CEA levels with tumour
extension was expected from plotting the preradio-
therapeutic serum level of â 2-microglobulin against the
CEA serum concentration for each of 163 patients
specified according to the TNM classification recom-
mended by the UICC (fig. 1). No correlation of the in-
dividual â 2-microglobulin concentrations with the
pre-therapeutic CEA concentrations is evident. How-
ever, iri the group of patients with distant metastatic
spread and elevated CEA levels 13/29 patients (45%)
have also a 2-microglobulin concentration in the
pathologic range (tab. 1, n2, n3, n4). In this subgroup
12/13 patients were older than 70 years and the elevated
0 2-microglobulin levels could also result from the
advanced age of the patients, since the data in table 1
demonstrate that the frequency of serum samples with
pathological â 2-microglobulin levels (> 2.5 mg/1) in-
creased with advancing age. On the other hand, the
CEA serum levels also exhibit an apparent age effect: in
the group of patients older than 70 years a distinctly
higher percentage of patients with pathological CEA
serum concentrations was registered; this could be due
to a higher percentage of patients with metastatic breast
cancer compared with other age groups.
In table 2 the age effect of the serum levels of both
markers within the 3 groups of patients with given
tumour extension is listed according to the 4 criteria of
CEA//J2-microglobulin serum levels. The number of
patients with pathological â 2-microglobulin levels
increases with age in about all subgroups (tab. 2, n2
and n4). For pathological CEA levels (tab. 2, n3 + n4)
this holds true only for the group of patients with
distant metastasis, due to the fact that our patients
older than 70 years have a higher incidence of metastasiz-
ing tumours (23/51 patients) compared with patients
between 60 and 70 years (8/31 patients) and patients
between 50 and 60 years (2/42). On the basis of the
results given in table 1 and 2 one cannot entirely exclude
an association of the 0 2-microglobulin serum concentra-
tion with tumour extension in breast cancer patients. A
more detailed characterization of a possible complemen-
tarity of 02-microglobulin and CEA as tumour markers
in breast cancer can be expected from the comparison
of the correlation of changes in serum concentration of
each marker with the course of malignant disease and
disease recurrence.
Correlation of 2~microglobulin and CEA levels
with the time course of disease
The possible complementarity of 02-microglobulin
and CEA as tumour markers in breast cancer was studied
by correlating the changes in the serum level of these
markers with the clinical course of disease. For this
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Tab. 2. Correlation of age and pre-radiotherapeutic serum /j2-microglobulin and CEA levels in patients with breast cancer within the
given classification of tumour extension (TNM classification).
Tumour extension
Ô Ö 0, No, Mo
T, N Ö Ï, Mo
M = l
Age
[a]
<50
50-59
60-69
>70
<50
50-59
60-69
>70
<50
50-59
60-69
>70
Samples with Mg/1 CEA/mg/l 02-™crogiobulm
<2/<2.5
ni
4
9
5
2
7
4
2
5
0
0
1
2
<2/>2.5
Ð2
0
2
1
0
1
2
1
3
0
0
1
2
>2/<2.5
Ð3
14
12
5
3
11
10
7
5
1
2
6
7
>2/>2.5
n4
0
Ú
2
4
0
0
0
6
1
0
0
12
Patients
total
n
18
24
13
9
19
16
10
19
2
2
8
23
Total 41 13 83 26 163
purpose serial determinations of the /32-microglobulin
and CEA levels were performed during radiotherapy and
during the post-treatment surveillance in a selected group
of 235 patients.
For the classification of the time courses of ^ -micro-
globulin and CEA serum levels we chose 4 categories:
1) increasing concentrations in the pathological range;
2) decreasing from pathological to normal;
3) unchanging in the pathological range (marked with an
asterisk in tab'. 3);
4) unchanging in the normal range.
The specification of the clinical course of disease was
essentially based on the diagnosis of local recurrence and
distant metastasis. Suspected recurrences due to various
clinical criteria, but still lacking final confirmation, were
not recorded as a positive diagnosis of recurrence.
In table 3 the /32-microglobulin and CEA time courses
are listed in relation to the status of malignant disease.
All possible combinations of the 2-microglobulin and
the CEA time course categories were observed. In
160/235 cases (68%) /32-microglobulin was silent, i.e.
the |82-microglobulin serum concentration remained in
the normal range throughout. Unchanging CEA levels in
the normal range were registered only for 87/235 patients
(37%). Excluding all cases with both markers silent,
there were only 28/235 cases (12%) with directly coinci-
dent /32-microglobulin and CEA time courses. ' '
Our follow-up study has been in progress now for 9-16
months depending on the time of entry of patients.
During this time, a local recurrence of disease was
detected in 9 patients, and distant metastases in 73 pa-
tients. The rate of false negative indications in the
/32-microglobulin follow-up has been very high: 53/82
cases (65%) with local recurrence or distant spread of
disease were not indicated, whereas only 3/82 false
negative indications (4%) were recorded in the CEA
follow-up.
In some of the 'false CEA positive' cases the pathologi-
cal CEA serum concentration were due to other non-
malignant disease known to induce increased CEA levels:
liver malfunction (n = 1), liver cirrhosis (n = 2), colitis
(n = 1). One patient with a 'false positive' indication in
the /32-microglobulin follow-up had an impaired renal
function known to be associated with increased /32-micro-
globulin levels (38,39).
Discussion
Carcinoma cells in culture have been found to produce
/32-microgJobulin at a higher concentration than non-
neoplastic cells (40,41). These findings lead to the
suggestion that /32-microgjlobulin is a potential tumour
marker. The results of our follow-up study of 235 breast
cancer patients, who had undergone radical mastectomy
and radiotherapy, do not support this suggestion when
changes of the /32-microglobulin serum levels are cor-
related >yith the clinical course of malignant disease. In
53/82 cases (65%) with disease recurrence false negative
indications of the./32-microglobulin time course were
registered. In contrast, the CEA follow-up showed only
3/82 (4%) false negative indications. These results cor-
respond to the data of a previous study carried out with
patients with carcinomas of the gastrointestinal tract
(42).
A distinctly higher percentage of cases with pathological
concentrations of j32-microg;lobulin and CEA was
recorded in the group of patients older than 70 years
when compared with the other age groups (tab. 1 and 2),
thus agreeing with previous studies{26,29,30). This
observation coincided with a higiher frequency of
metastatic disease in the elderly patients as compared to
the other age groups. In case of 02-microglobulin, the
J. Om; Chem. Clin. Biochem, / Vol. 19,1981 /No. 6
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; Tab. 3. Correlation of the changes of 02-microglobulin and CEA serum concentrations during and after radiotherapy with the clinical
course of malignant disease.
Time courses: / increasing concentrations of 02-microglobulin or CEA in the pathological range; V decreasing from
! pathological to normal; *-* unchanging in the pathological range; -^unchanging in the normal range.
Markers Clinical course of disease
Time course No recurrence Local
2- CEA to date recurrence
micro-
globulin
3a - 0
ê n
1 liver malfunction
la 1
; Vi /
,1
j la 1 lymphnode
>l
 *-> /^
6a 3
1 lymphnode
! ->· /
1
I
' ' / V. 3
V \ 6
*-* \ 2
-*· ^ 21 1
2a
t *-»·
la
÷ ->\
la 1*-» *->
 3
la 1 lymphnode
2 (liver cirrrhosis)
1 (colitis)
/ -* 31 (renal disease)
\ -* 8
*-> -> 3
^ ^ 70
Total 153 9
Total False indications
Distant patients Negative Positive
metastases
 02- CEA 02- CEA
micro- micro-
globulin globulin
4 bone
2 liver , . „a . ^a1 lung 14 - - 3 a + l 3 a + l
3 multiple
1 bone
1 liver 5 4 - - la
1 lung
1 bone
1 brain
 n a ^
3 liver " " - l 1
4 multiple
12 bone
1 brain
7 liver 39 32 6a
6 lung
3 multiple
3 - 0 3 -
6 0 0
2 - 0 2 -
22 1 1
1 brain
2 liver 6 2a 2a
1 lung
1 bone
1 liver ò 4 ia
1 lung * 4 *
1 multiple
2 Iiver
 8 - - l a +3 la + 31 multiple * * * A 3
5 bone
2 S? 27 10 - - la+16
1 multiple
4 - 0 4 -
8 0 0
3 - 0 3 -
1 multiple ^ ^ 2 - -
1 lung
73 235 53 3 7a+16 16a+20
recurrence suspected but not yet clinically confirmed
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incidence of pathological j32-microglobulin levels was
two-fold higher in patients with distant metastases than
in patients with localized disease. This finding may
indicate a direct association of the serum ^-micro-
globulin level with malignant growth. However, a
detailed interpretation is complicated due to an age
effect (25,30), possibly induced by some clinical con-
ditions associated with advanced age, including renal
and immune disorders, known to markedly increase the
serum level of 02-microglobulin (19,38, 39). In contrast,
the criteria of CEA as a tumour marker in breast cancer
have been fully established in previous investigations
(31,37) and the influence of distant spread of disease
on the CEA serum concentration regardless of age
became evident (28,27,31—36). The high incidence of
pathological CEA levels in our group of breast cancer
patients as compared with prior studies (14,15) is
related to the fact that the present study did not deal
with an unselected group of newly diagnosed patients.
The valuation of 'false positive' indications in table 3 is
somewhat arbitrary. 7/23 'false positive' indications in
the /32-microglobulin follow-up and 16/36 'false posi-
tive' indications in the CEA follow-up are cases where
recurrence or metastatic spread is suspected but not yet
clinically confirmed. With advancing time of clinical
surveillance these numbers in table 3 may change if
suspected recurrences are clinically confirmed. In a
longer follow-up recurrences might be also expected in
the group of 'correct negative cases', but according to
our experience these cases have a distinctly lower
probability of recurrence of disease (37).
A direct evaluation of j32-microglobulin as a tumour
marker in breast cancer was made from the correlation
with the clinical course of disease and disease recurrence..
As shown in table 3, in the j32-rriicroglobulin follow-up,
46/73 (63%) cases of metastatic spread and 7/9 cases:/
(78%) with local recurrence were not indicated by
pathologic j32-microgiobulin serum concentrations.
Therefore, since the clinical course of disease coincided
with the changes of |32-microglobulin levels only in the
minority of cases, |82-microglobulin does not appear to
fulfill the criteria of a tumour marker in breast cancer.
Ori the basis of these results it is suggested that the
changes of /32-microglobulin serum levels seen in
carcinomas may reflect a biological event, possibly
lymphocyte stimulation (22), frequently associated
with the malignant growth.
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